Addendum: LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin’s lymphoma models and in cells deficient in DNA damage repair
Metrics: PDF 158 views | ?
1Lantern Pharma Inc., Plano, TX 75024, USA
2Department of Medicine, Duke University, Durham, NC 27708, USA
3Data Driven Bioscience, Durham, NC 27707, USA
Published: July 20, 2023
Copyright: © 2023 Zhou et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
This article has an addendum: Wet-lab experiments conducted at Data Driven Bioscience, Rincon Biosciences, Reprocell Inc., intoDNA, and Toxys Europe were funded by Lantern Pharma Inc.
Original article: Oncotarget. 2023; 14:597-611. DOI: https://doi.org/10.18632/oncotarget.28454.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.